-
Jan 18, 2025 | 
mdpi.com | Kara Cicero |Rahul Banerjee |Mary Kwok |Danai Dima
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Dec 4, 2024 | 
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Nov 21, 2024 | 
nature.com | Carlos Bravo-Pérez |Yasuo Kubota |Simona Pagliuca |Danai Dima |Hetty Carraway |Valeria Visconte
AbstractPast studies described occasional patients with myeloid neoplasms (MN) and coexistent large granular lymphocytic leukemia (LGLL) or T-cell clonopathy of unknown significance (TCUS), which may represent expansion of myeloid clonal hematopoiesis (CH) as triggers or targets of clonal cytotoxic T cell reactions. We retrospectively analyzed 349 LGLL/TCUS patients, 672 MN patients, and 1443 CH individuals to establish the incidence, genetic landscape, and clinical phenotypes of CH in LGLL.
-
Aug 27, 2024 | 
onlinelibrary.wiley.com | Utkarsh Goel |Danai Dima |James Davis |Nausheen Ahmed
What is the new aspect of your work? This multicenter retrospective study represents the largest case series describing the use of standard of care chimeric antigen receptor (CAR) T-cell therapy in patients with AL amyloidosis and concurrent relapsed/refractory multiple myeloma. What is the central finding of your work?
-
Jul 29, 2024 | 
nature.com | Fauzia Ullah |Danai Dima |Hetty Carraway |Chao-Yie Yang |Carmelo Gurnari |Valeria Visconte | +1 more
TO THE EDITOR:FMS-like receptor tyrosine kinase 3 (FLT3) expression is almost exclusively found in the myeloid compartment [1]. The FLT3 protein consists of an extracellular region containing the ligand-binding site, a transmembrane domain, a cytoplasmic juxtamembrane domain, and a tyrosine kinase domain (TKD).
-
Jun 20, 2024 | 
onlinelibrary.wiley.com | Danai Dima |Nerea Lopetegui-Lia |Olisaemeka Ogbue |Bennett Osantowski
1 INTRODUCTION Over the last decade, significant drug advancements have radically shifted the treatment paradigm of melanoma leading to improved patient outcomes.1-3 Immunotherapy (IO) with anti-CTLA4 and anti-PD1 monoclonal antibodies, as well as targeted therapy (TT) with BRAF/MEK inhibitors, demonstrated improved survival of patients with metastatic disease.4-8 More recently, these treatments have been studied in the adjuvant (adj) setting for resected stage III/IV melanoma, also showing...
-
Jun 14, 2024 | 
onlinelibrary.wiley.com | Danai Dima |Utkarsh Goel |Aishwarya Sannareddy |Nnaemeka Ibeh
1 INTRODUCTION Renal impairment is a multiple myeloma (MM) defining event and it is present in up to 50% of patients.1 Myeloma cast nephropathy (MCN) is the most common etiology of kidney failure in MM and accounts for approximately 30% of all cases.
-
May 30, 2024 | 
nature.com | Danai Dima |James Davis |Hussein Awada |Faiz Anwer |Shahzad Raza |Zahra Mahmoudjafari | +2 more
AbstractThe presence of extramedullary disease (EMD) has been associated with poor outcomes in patients with relapsed-refractory multiple myeloma (RRMM). Herein, we report the outcomes of RRMM patients who were treated with standard-of-care (SOC) chimeric antigen receptor (CAR) T-cell therapy and had active extraosseous EMD before the infusion. Data were retrospectively collected from patients at three US institutions with the intent to receive SOC CAR T.
-
May 11, 2024 | 
nature.com | Hussein Awada |Tariq Kewan |Danai Dima |Hassan Awada |Simona Pagliuca |Valeria Visconte
To the Editor:Karyotypic aberrations of chromosome (chr) 6 include duplications (trisomy 6 [+6]), deletions of its short arm (del6p), uniparental disomy 6p (UPD6p), as well as various microduplications and microdeletions. Lesions involving 6p are of particular interest as they point toward HLA locus involvement, including loss of heterozygosity and/or haploinsufficiency, as pathogenic drivers resulting from deletions and UPD6p [1, 2].
